Longevity Review logoLongevity Review
Escape VelocityYour OddsHallmarksInterventionsResearchTrialsBooksAboutRead the index

Reading

Books on aging, graded against the evidence

The popular books on aging and longevity, each read against the grades in the intervention catalog: what holds up, and where it runs ahead of the evidence. Every verdict links to the grades it is measured against, so you can check it.

As an Amazon Associate I earn from qualifying purchases. Links go to Amazon and are chosen by the evidence grade, never by the commission: how we choose.

Holds up

What it tells readers to believe or do matches the grades here.

Why We Die

The New Science of Aging and the Quest for Immortality

Venki Ramakrishnan(2024)

See the book on Amazon (opens in new tab)

A Nobel-winning molecular biologist's tour of why bodies wear out, from DNA damage and protein upkeep to senescence, and of what the longevity industry is selling.

The most careful general book on the biology of aging. Its caution about near-term radical life extension is the same reading this site's escape-velocity index gives: real mechanisms, very little human proof.

Measured againstEscape-velocity indexCaloric Restriction (CR)G2Rapamycin (Sirolimus)G4

Super Agers

An Evidence-Based Approach to Longevity

Eric Topol(2025)

See the book on Amazon (opens in new tab)

A cardiologist and genomics researcher on preventing the major diseases of aging, built around people who reach old age without them.

Treats longevity as preventing age-related disease with tools that have outcome data. Its practical roadmap (strength training, sleep, diet, social connection) lines up with the grades here, and its look ahead at AI and molecular risk prediction is presented as the future, not the present.

Measured againstResistance TrainingG1GLP-1 Receptor Agonists (Semaglutide, Tirzepatide)G1Sleep OptimizationG3Social ConnectionG3

Sound core, ahead in places

The core matches the grades; specific claims run past them.

Outlive

The Science and Art of Longevity

Peter Attia with Bill Gifford(2023)

See the book on Amazon (opens in new tab)

A physician's program against the four diseases that kill most people (heart disease, cancer, neurodegeneration and metabolic disease), with exercise at its center.

Its core holds up: strength, cardiorespiratory fitness and ApoB are among the few levers graded proven in humans here. It runs ahead where it gets specific: the Zone 2 prescription is more precise than the trials behind it, and its interest in rapamycin rests on mouse data.

Measured againstResistance TrainingG1Zone 2 & VO2max CardioG1ApoB (Apolipoprotein B)G1Rapamycin (Sirolimus)G4

Ageless

The New Science of Getting Older Without Getting Old

Andrew Steele(2020)

See the book on Amazon (opens in new tab)

A computational biologist's survey of the hallmarks of aging and the treatments aimed at each, from senolytics to cellular reprogramming.

The clearest map of the treatment pipeline for a general reader, and honest that most of it works in mice so far. Its optimism about timing runs ahead: senolytics and reprogramming are still animal-stage or early-stage in the grades here.

Measured againstThe hallmarks of agingSenolytics: Dasatinib + Quercetin (D+Q)G4Partial Reprogramming (Yamanaka Factors)G5

Ending Aging

The Rejuvenation Breakthroughs That Could Reverse Human Aging in Our Lifetime

Aubrey de Grey with Michael Rae(2007)

See the book on Amazon (opens in new tab)

The damage-repair plan (SENS) that sorts aging into seven kinds of molecular and cellular damage and proposes a fix for each, from the researcher who coined longevity escape velocity, the idea this site measures.

The framework is serious and shaped the field: clearing senescent cells, one of its repairs, is now a real drug class. Its timelines were not: nearly two decades on, none of its repairs is proven in people, which is why the escape-velocity index here is still low.

Measured againstEscape-velocity indexSenolytics: Dasatinib + Quercetin (D+Q)G4Mitochondrial Transfer / TransplantationG5Stem Cell TherapiesG7

Runs ahead of the evidence

Read it for the ideas, with the grades open beside it.

Lifespan

Why We Age, and Why We Don't Have To

David A. Sinclair with Matthew D. LaPlante(2019)

See the book on Amazon (opens in new tab)

A Harvard geneticist's theory that aging is a loss of epigenetic information, and his case for sirtuins, NAD+ boosters and resveratrol.

A vivid read on a real research idea, but the practical chapters outrun the evidence. The author describes taking NMN, resveratrol and metformin himself; graded here, NAD+ boosters raise a marker without a shown benefit, resveratrol's human evidence is contested, and metformin's longevity case rests on confounded data.

Measured againstNAD+ Precursors (NMN & Nicotinamide Riboside)G2ResveratrolG6MetforminG3Partial Reprogramming (Yamanaka Factors)G5

The Singularity Is Nearer

When We Merge with AI

Ray Kurzweil(2024)

See the book on Amazon (opens in new tab)

The futurist's update of his 2005 book: AI compounding progress across the sciences, with medicine soon adding more than a year of life expectancy per year.

Worth reading as the strongest optimist's case, not as a forecast of record. Among the named experts weighed in this site's arrival-year model, his date is the earliest, and the evidence index shows how far the biology is from any date that close.

Measured againstArrival-year modelEscape-velocity index
Longevity Review logoLongevity Review

A continuously updated, evidence-graded systematic review of longevity science. Educational only, not medical advice.

Product

  • Escape Velocity
  • Your Odds
  • Hallmarks
  • Interventions
  • Research
  • Trials
  • Books
  • About

Legal

  • Methodology
  • Privacy Policy
  • Terms of Service
  • Support
© 2026 Longevity Review. All rights reserved.